Van Lanschot Kempen Investment Management N.V. Has $258.51 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Van Lanschot Kempen Investment Management N.V. cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 446,129 shares of the medical research company’s stock after selling 71,135 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.2% of Van Lanschot Kempen Investment Management N.V.’s investment portfolio, making the stock its 12th largest holding. Van Lanschot Kempen Investment Management N.V.’s holdings in Thermo Fisher Scientific were worth $258,509,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. Brighton Jones LLC grew its stake in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the 2nd quarter worth $170,000. Raymond James Financial Inc. grew its position in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after purchasing an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in Thermo Fisher Scientific by 0.4% in the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after purchasing an additional 2,262 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on TMO. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Finally, DZ Bank began coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $608.95.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $468.80 on Friday. The company has a 50-day moving average of $479.14 and a 200-day moving average of $527.68. The company has a market capitalization of $174.22 billion, a price-to-earnings ratio of 25.77, a PEG ratio of 2.11 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.